Novartis's paradigm-shifting, blockbusting heart failure drug trounces enalapril
This article was originally published in Scrip
Executive Summary
Novartis's novel heart failure therapy LCZ696 led to 20% fewer cardiovascular deaths, 21% fewer hospitalizations and a 16% reduction in all-cause mortality compared with the old mainstay, ACE inhibitor therapy enalapril, in the much-anticipated PARADIGM-HF study, in results that could change clinical practice and open up a $10bn market. A US filing for the product is planned by the end of this year, with an EU submission following in early 2015.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.